Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02942381
Other study ID # 2016(1057)
Secondary ID
Status Completed
Phase Phase 2
First received October 14, 2016
Last updated February 2, 2018
Start date September 13, 2016
Est. completion date January 8, 2018

Study information

Verified date February 2018
Source Peking University First Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.


Description:

Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis worldwide. Several studies indicated that 6-43% of IgA nephropathy patients would develop end-stage kidney disease (ESKD) over a period of 10 years. The clinical risk factors for progression are hypertension, proteinuria, impaired renal function and histologic lesions at presentation. There is no well accepted optimal therapy for patients with IgA. Current established therapies include full RAS inhibition and optimal blood pressure control for patients with proteinuria and/or hypertension.

Hydroxychloroquine has been used for many years to treat malaria. It is also used to treat systemic lupus erythematosus, rheumatic disorders like rheumatoid arthritis and Sjögren's Syndrome. Recently, several studies found that Hydroxychloroquine could reduce the risk of ESRD in patients with lupus nephritis. The mechanism of the treatment wasn't well known so far. Some investigators found that Hydroxychloroquine increases lysosomal pH in antigen presenting cells. In inflammatory conditions, it blocks toll-like receptors on plasmacytoid dendritic cells (PDCs). Toll-like receptor 9 (TLR 9), which recognizes DNA-containing immune complexes, leads to the production of interferon and causes the dendritic cells to mature and present antigen to T cells. Hydroxychloroquine, by decreasing TLR signaling, reduces the activation of dendritic cells and the inflammatory process.

The pathogenesis of IgA nephropathy included the deposition of immune complex containing IgA in mesangium and causing local immune activation and injury to kidney. Therefore, Hydroxychloroquine might have the potential effect of anti-inflammation in patients with IgA nephropathy, reduced the proteinuria and had the renal protect effect.

The investigators study will recruit IgA nephropathy patients with proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB. The patients were treated with Hydroxychloroquine 200-400mg/d according to eGFR. The proteinuria will recorded every two months and total four months. Then, the drug will be stopped for two months for observation of change of proteinuria.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date January 8, 2018
Est. primary completion date January 8, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- primary IgA nephropathy

- age 18-75 years

- proteinuria range from 0.75 to 3.5g/d even after three-month treatment by sufficient ACEi/ARB

- eGFR>30ml/min/1.73m2

Exclusion Criteria:

- immune suppressive agent in recent one years

- crescent glomerulonephritis, might use immune suppressive agent

- chronic hepatic disease

- myocardial infarction

- malignant hypertension

- stroke

- malignant tumor

- retinopathy

- other contraindication of Hydroxychloroquine

- pregnancy and breastfeeding women

- life expectancy for less than 6 months

- in other clinical trials

- not suitable for the study judged by investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Hydroxychloroquine Sulfate
200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
Placebo


Locations

Country Name City State
China Peking University First Hospital BeiJing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University First Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proteinuria (g/d) every two months(total six months)
Secondary Albuminuria and creatinine ratio(mg/g) every two months(total six months)
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04400019 - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM) Phase 2/Phase 3
Completed NCT04347798 - IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
Completed NCT04652648 - Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts Phase 4
Withdrawn NCT04354441 - Effect of Hydroxychloroquine in COVID-19 Positive Pregnant Women Phase 2
Completed NCT04434144 - A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh
Active, not recruiting NCT04363827 - Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) Phase 2
Completed NCT04376814 - Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19 N/A
Enrolling by invitation NCT04340349 - Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals Early Phase 1
Completed NCT02648464 - Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial Phase 4
Not yet recruiting NCT05647330 - Hydroxychloroquine Combined With Gemcitabine in the Treatment of Advanced Non-small Cell Lung Cancer Phase 2
Withdrawn NCT04349228 - Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals Phase 3
Recruiting NCT04363450 - Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) Phase 3
Not yet recruiting NCT04352946 - HEalth Care Worker pROphylaxis Against COVID-19: The HERO Trial Phase 3
Recruiting NCT05451277 - At the Heart of the Matter - Speckle Tracking Echocardiography in Lupus Mothers and Their Offspring